BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Facciorusso A, Amoruso A, Neve V, Antonino M, Prete VD, Barone M. Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol 2014; 6(11): 793-799 [PMID: 25429317 DOI: 10.4254/wjh.v6.i11.793] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 de la Nuez Veulens A, Ginarte YMÁ, Fernandez RER, Leclerc F, Cabrera LAM. Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism. J Mol Model 2022;28:31. [PMID: 34997307 DOI: 10.1007/s00894-021-05022-6] [Reference Citation Analysis]
2 Subedi A, Suresh Kumar VC, Sharma Subedi A, Sapkota B. A Review of Hepatorenal Syndrome. Cureus 2021;13:e16084. [PMID: 34367745 DOI: 10.7759/cureus.16084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Gilloteaux J, Bouchat J, Brion J, Nicaise C. The osmotic demyelination syndrome: the resilience of thalamic neurons is verified with transmission electron microscopy. Ultrastructural Pathology 2020;44:450-80. [DOI: 10.1080/01913123.2020.1853865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Triolo M, La Mura V. Management of Ascites. Liver Diseases 2020. [DOI: 10.1007/978-3-030-24432-3_65] [Reference Citation Analysis]
5 Facciorusso A. Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.Ther Clin Risk Manag. 2019;15:1383-1391. [PMID: 31819465 DOI: 10.2147/TCRM.S205328] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Mansour D, Mcpherson S. Management of decompensated cirrhosis. Clin Med 2018;18:s60-5. [DOI: 10.7861/clinmedicine.18-2-s60] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
7 Mansour D, McPherson S. Management of decompensated cirrhosis. Clin Med (Lond) 2018;18:s60-5. [PMID: 29700095 DOI: 10.7861/clinmedicine.18-2-s60] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Jiménez JV, Carrillo-Pérez DL, Rosado-Canto R, García-Juárez I, Torre A, Kershenobich D, Carrillo-Maravilla E. Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach. Dig Dis Sci 2017;62:1855-71. [PMID: 28501971 DOI: 10.1007/s10620-017-4597-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
9 Korenblat K. Management of ascites in cirrhosis and portal hypertension. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00081-9] [Reference Citation Analysis]
10 Li H, Jin Z, Wu LJ, Bai YL, Gu JX, Jin JJ. Terlipressin plus albumin for treatment of type 1 hepatorenal syndrome: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4805-4812 [DOI: 10.11569/wcjd.v24.i36.4805] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Pericleous M, Sarnowski A, Moore A, Fijten R, Zaman M. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations. Eur J Gastroenterol Hepatol 2016;28:e10-8. [PMID: 26671516 DOI: 10.1097/MEG.0000000000000548] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 8.3] [Reference Citation Analysis]